SCHRODINGER INC

Inside Schrodinger’s latest Rule 10b5‑1 trades: Karen Akinsanya sells at $30, buys at $4.34, signaling management confidence and a cautious outlook for the biotech‑software stock.

Schrödinger Inc.’s CFO sells 875 shares for $15.60 each—an automated tax‑plan move, not a strategic shift, amid a volatile market and mixed insider buying.

Schrödinger’s insider grant spree signals confidence in its AI‑driven drug‑discovery platform amid value‑based care trends, but investors should watch clinical milestones and earnings to gauge true upside.

Schrodinger insider buys reveal executive confidence in its drug‑discovery platform, underscoring strategic growth amid market volatility.